gemcitabine has been researched along with oleanolic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chun, KH; Kim, J; Kim, Y; Lim, JW; Yoon, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Al-Radhi, M; Awsh, M; Baldi, S; Chu, P; Fang, J; Jia, J; Li, X; Ma, X; Peng, J; Safi, M; Shopit, A; Shu, X; Tang, Z; Wang, F; Wang, S | 1 |
3 other study(ies) available for gemcitabine and oleanolic acid
| Article | Year |
|---|---|
Discovery of ursolic acid prodrug (NX-201): Pharmacokinetics and in vivo antitumor effects in PANC-1 pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Humans; Mice, SCID; Pancreas; Pancreatic Neoplasms; Prodrugs; Triterpenes; Ursolic Acid; Xenograft Model Antitumor Assays | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Oleanolic Acid; Pancreatic Neoplasms; Trypsin Inhibitor, Kazal Pancreatic | 2021 |